<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04963296</url>
  </required_header>
  <id_info>
    <org_study_id>CA42750</org_study_id>
    <secondary_id>2020-005760-57</secondary_id>
    <nct_id>NCT04963296</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus</brief_title>
  <acronym>ALLEGORY</acronym>
  <official_title>A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety of Obinutuzumab in Patients With Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and&#xD;
      safety of obinutuzumab versus placebo in participants with active, autoantibody-positive&#xD;
      systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2021</start_date>
  <completion_date type="Anticipated">November 13, 2027</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants who Achieve Systemic Lupus Erythematosus Responder Index (SRI[4]) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>SRI(4) requires reduction from baseline of &gt;=4 points in the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), no new systems or organs affected, as defined by &gt;=1 new British Isles Lupus Assessment Group (BILAG) A or &gt;=2 new BILAG B items compared with baseline using BILAG-2004, and no worsening from baseline of &gt;=0.30 points on a 3-point Physician's Global Assessment Visual Analogue Scale (PGA-VAS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve SRI(6) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>SRI(6) requires reduction from baseline of &gt;=6 points in the SLEDAI-2K, no new systems or organs affected, as defined by &gt;=1 new BILAG A or &gt;=2 new BILAG B items compared with baseline using BILAG-2004, and no worsening from baseline of &gt;=0.30 points on a 3-point PGA-VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Sustained Corticosteroid Control</measure>
    <time_frame>From Week 40 to Week 52</time_frame>
    <description>No treatment with prednisone &gt;=5 mg/day (or equivalent) and no receipt of intravenous, intramuscular, or intra-articular corticosteroids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Sustained SRI(4) Response</measure>
    <time_frame>From Week 40 to Week 52</time_frame>
    <description>Achievement of SRI(4) at all study visits from Week 40 through Week 52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Reduction of all baseline BILAG-2004 A items to B/C/D and baseline BILAG-2004 B items to C/D; no new systems or organs affected, as defined by &gt;=1 new BILAG A or &gt;=2 new BILAG B items compared with baseline; no net increase in SLEDAI-2K score from baseline; and no worsening from baseline of &gt;=0.30 points on a 3-point PGA-VAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve SRI(8) at Week 52</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve SRI(4) at Week 24</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Clinical SRI(4) at Week 52</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve SRI(4) at Week 52 on Low-dose Corticosteroids</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants who Achieve Lupus Low Disease Activity State (LLDAS) at Week 52</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First BILAG Flare</measure>
    <time_frame>From baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale</measure>
    <time_frame>From baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 36-Item Short Form Survey, Version 2 (SF-36 v2) Bodily Pain Domain Scale</measure>
    <time_frame>From baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in SF-36 v2 Physical Component Summary Scale</measure>
    <time_frame>From baseline to Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>From baseline to approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events of Special Interest (AESIs)</measure>
    <time_frame>From baseline to approximately 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Obinutuzumab</measure>
    <time_frame>Double blind period: At Weeks 2, 4, 12, 24, 26, 36, 52 and at early study discontinuation visit; Open label period: At Weeks 54, 56, 58, 66, 78, 80, 90, 104 and at early study discontinuation visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Anti-drug Antibodies (ADAs) at Baseline</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with ADAs During the Study</measure>
    <time_frame>Up to approximately 6 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive obinutuzumab 1000 milligrams (mg) intravenous (IV) infusions on Day 1 and Weeks 2, 24 and 26.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo participants will receive obinutuzumab matched placebo on Day 1 and Weeks 2, 24 and 26.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Obinutuzumab will be administered by IV infusion at a dose of 1000 mg on Day 1 and Weeks 2, 24 and 26.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <other_name>Gazyva, GA101, RO5072759</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching obinutuzumab will be administered by IV on Day 1 and Weeks 2, 24 and 26.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetaminophen/Paracetamol</intervention_name>
    <description>Acetaminophen 650-1000 mg will be administered as premedication prior to infusions.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diphenhydramine hydrochloride</intervention_name>
    <description>Diphenhydramine 50 mg will be administered as premedication prior to infusions.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>Methylprednisolone 80 mg IV will be administered as premedication prior to infusions.</description>
    <arm_group_label>Obinutuzumab</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of SLE according to the 2019 European League Against Rheumatism/American&#xD;
             College of Rheumatology (EULAR/ACR) Classification Criteria &gt;=12 weeks prior to&#xD;
             screening&#xD;
&#xD;
          -  Anti-nuclear antibody (ANA) &gt;=1:80, or anti-dsDNA and/or anti-Sm antibodies above the&#xD;
             upper limit of normal (ULN), as determined by the central laboratory at screening&#xD;
&#xD;
          -  Low C3, C4, and/or CH50 as determined by the central laboratory at screening&#xD;
&#xD;
          -  High disease activity at screening, based on; BILAG-2004 (level A disease in &gt;=1 organ&#xD;
             system and/or Level B disease in &gt;=2 organ systems), Systemic Lupus Erythematosus&#xD;
             Disease Activity Index 2000 (SLEDAI-2K) (score &gt;=8) and Physician's Global Assessment&#xD;
             (PGA) (score &gt;=1.0 on a 0 to 3 visual analogue scale [VAS])&#xD;
&#xD;
          -  High disease activity on Day 1, based on; SLEDAI-2K (score &gt;=8) and PGA (score &gt;=1.0&#xD;
             on a 0 to 3 VAS)&#xD;
&#xD;
          -  Current receipt of &gt;=1 of the following classes of standard therapies for the&#xD;
             treatment of SLE at stable doses: oral corticosteroid (OCS), antimalarials,&#xD;
             conventional immunosuppressants&#xD;
&#xD;
          -  Other inclusion criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Presence of significant lupus-associated renal disease and/or renal impairment&#xD;
&#xD;
          -  Receipt of an excluded therapy, including any anti-CD20, anti-CD19 therapy less than 9&#xD;
             months prior to screening or during screening; or cyclophosphamide, tacrolimus,&#xD;
             ciclosporin, or voclosporin during the 2 months prior to screening or during screening&#xD;
&#xD;
          -  Significant or uncontrolled medical disease which, in the investigator's opinion,&#xD;
             would preclude patient participation&#xD;
&#xD;
          -  Known active infection of any kind or recent major episode of infection&#xD;
&#xD;
          -  Intolerance or contraindication to study therapies&#xD;
&#xD;
          -  Other exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: CA42750 https://forpatients.roche.com/</last_name>
    <phone>88-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arthritis &amp; Rheumatology of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwell Health Division of Rheumatology</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prolato Clinical Research Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Organizacion Medica de Investigacion</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>DOM Centro de Reumatología</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <zip>C1111AAJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HOPITAL COCHIN; Internal Medicine Department</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto de Ginecología y Reproducción</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Autonomous Healthcare Institution of Yaroslavl region &quot;Clinical Hospital 9&quot;</name>
      <address>
        <city>Yaroslavl</city>
        <state>Jaroslavl</state>
        <zip>150042</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Federal State Budgetary Scientific Institution Research Institute of Rheumatology V.A. Nasonova</name>
      <address>
        <city>Moscow</city>
        <state>Moskovskaja Oblast</state>
        <zip>115522</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SBHI of Yaroslavl Region Clinical Hospital #3</name>
      <address>
        <city>Yaroslavl</city>
        <state>Volgograd</state>
        <zip>150051</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Scient Res Med Ctr Your Health</name>
      <address>
        <city>Kazan</city>
        <zip>420064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SBEI of HPI The 1st Moscow State Medical University n.a. I.M. Sechenov of MOH of RF</name>
      <address>
        <city>Moscow</city>
        <zip>119021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ryazan State Medical University Named after I.P.Pavlov</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>FGBU &quot;Federal Medical and Research Center named after V.A.Almazov&quot; Russian Ministry of Health</name>
      <address>
        <city>Sankt-Petersburg</city>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Republican clinical hospital named after G.G. Kuvatov</name>
      <address>
        <city>UFA</city>
        <zip>450005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Panorama Medical Center; Rheumatology</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>TREAD Research</name>
      <address>
        <city>Cape Town</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Precise Clinical Solutions (Pty) Ltd</name>
      <address>
        <city>Chatsworth</city>
        <zip>4092</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenacres Hospital</name>
      <address>
        <city>Port Elizabeth</city>
        <zip>6045</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Netcare Umhlanga Medical Centre; Rheumatology</name>
      <address>
        <city>Umhlanga</city>
        <zip>4319</zip>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon; Servicio de Reumatología</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>France</country>
    <country>Peru</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

